华东医药：雷珠单抗注射液上市许可申请获受理

Core Viewpoint - The announcement indicates that East China Pharmaceutical's subsidiary has received a notice of acceptance for the marketing authorization application of Ranibizumab injection, marking a significant progress in the drug's development [1] Company Summary - East China Pharmaceutical's wholly-owned subsidiary, Hangzhou Zhongmei East China Pharmaceutical Co., Ltd., has submitted a marketing authorization application for Ranibizumab injection, which has been accepted by the National Medical Products Administration [1] - The total investment in the research and development of Ranibizumab injection amounts to approximately 220 million yuan [1] - The acceptance of the application is an important milestone in the drug's development process, which is expected to enhance the company's core competitiveness in the treatment of various retinal diseases in the long term [1] Industry Summary - Ranibizumab injection is indicated for the treatment of various retinal diseases in adults and premature infants, highlighting its potential market relevance [1] - The acceptance of the marketing application is a positive development for the industry, as it reflects ongoing innovation and progress in the treatment of eye diseases [1]